Late Phase Development
We currently have an active pipeline of new cancer care products in various stages of development, including compounds in Phase III clinical development.
Anamorelin is a novel, orally available, selective ghrelin receptor agonist that mimics the appetite-enhancing and anabolic effects of the ghrelin hormone.
- Approved in Japan
- Phase III clinical studies (SCALA) ongoing globally